Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2025-05-13 Capital/Financing Update
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
Letter to eligible shareholders 2 pages 209.5KB
Capital/Financing Update Classification · 95% confidence The document is a letter dated 14 May 2025 addressed to shareholders of Percheron Therapeutics Limited regarding a Loyalty Options Offer. It details the terms of a non-renounceable pro-rata bonus offer of options to existing shareholders, including the record date, offer details, and how to access the prospectus. The document references the lodgement of the prospectus with ASIC and ASX and provides an indicative timetable for the offer. There is no financial data, earnings information, or management discussion present. The document is an announcement of a capital raising activity (issuance of options) but no funds will be raised as the options are issued for nil consideration. This fits the category of a Capital/Financing Update (CAP) as it relates to the company's capital structure and shareholder options issuance. The document length is under 5,000 characters and contains substantive offer details, so it is not merely a report publication announcement or regulatory filing. Therefore, the best classification is CAP with high confidence.
2025-05-13 English
Letter to ineligible shareholders 2 pages 142.6KB
Capital/Financing Update Classification · 95% confidence The document is a notice dated 14 May 2025 addressed to shareholders of Percheron Therapeutics Limited regarding a Loyalty Options Offer. It explains eligibility criteria for shareholders to participate in a pro-rata bonus offer of options and specifically informs certain shareholders that they are ineligible to participate. The document references the Corporations Act and ASX Listing Rules, and it is a communication about the terms and eligibility of a capital raising offer. It does not contain financial statements, earnings data, or detailed financial analysis. It is not a full report but rather an announcement related to a capital raising activity (the issuance of options). The document length is 3218 characters, which is relatively short and consistent with an announcement letter. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-05-13 English
Bonus Loyalty Option Offer 46 pages 811.5KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 7 May 2025 from Percheron Therapeutics Limited regarding a bonus loyalty option offer to existing shareholders. It includes detailed information about the offer, terms and conditions, key dates, and a prospectus lodged with ASIC. The content focuses on a capital raising event through issuing unquoted options to shareholders on a pro-rata basis for no consideration. There is no financial performance data, earnings information, or management discussion of results. The document is not a report but an announcement of a capital raising offer and related prospectus. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offer information, supporting a high confidence classification as CAP.
2025-05-06 English
Proposed issue of securities - PER 5 pages 20.2KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3B form, which is a standard ASX announcement format used for the proposed issue of securities, specifically a bonus issue of unquoted options. It includes details such as the entity name, announcement date, security codes, issue ratios, record and issue dates, and references to a prospectus. The content is focused on the announcement of a capital change event (bonus issue) rather than a full financial report or other types of filings. The document length is about 6,592 characters, which is consistent with a detailed announcement but not a full report. Therefore, the document fits the category of Share Issue/Capital Change (SHA).
2025-05-06 English
Quarterly Activities Report and Appendix 4C 10 pages 433.1KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement titled 'Quarterly Activities Report and Appendix 4C' for the quarter ended 31 March 2025. It provides a detailed update on the company's operational progress, strategic decisions, clinical trial wind-down, partnering discussions, financial position including cash flow statements, and shareholder meeting results. The inclusion of the Appendix 4C cash flow report, which is a regulatory quarterly cash flow statement required by ASX Listing Rules, confirms this is a quarterly report. The document contains substantive financial data and analysis for the quarter, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q3 2025
2025-04-29 English
Results of General Meeting 2 pages 189.4KB
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an ASX announcement dated 24 April 2025 reporting the results of a General Meeting of shareholders. It includes detailed poll voting results on resolutions concerning the removal and appointment of directors. The text references compliance with Listing Rule 3.13.2 and Section 251AA(1) of the Corporations Act, which relate to disclosure of voting results. The document is concise (4465 characters) and focuses solely on the official voting outcomes of the meeting, not the meeting materials or presentations themselves. This matches the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA).
2025-04-23 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.